Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact email@example.com
SOURCE Sigilon Therapeutics
CAMBRIDGE, Mass., Jan. 2, 2018 /PRNewswire/ -- Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced the company will present at the following conferences in January. Presentation details are as follows:
Biotech Showcase 2018
Paul Wotton, Ph.D., Chief Executive Officer
Monday, Jan. 8, 2018
1:45 p.m. PST
Room Franciscan C, Hilton San Francisco Union Square Hotel
Cell & Gene Therapy World 2018
David Peritt, Ph.D., Chief Technology Officer
Wednesday, Jan. 24, 2018
2:35 p.m. EST
Hyatt Regency Miami
About Sigilon Therapeutics
Founded and created by Flagship Pioneering, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics' Afibromer™ technology platform include cell implants that act as responsive "living therapeutics," providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.
In addition to Flagship Pioneering, Sigilon Therapeutics' co-founders include Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology Institute of Medical Engineering and Science, Department of Chemical Engineering and Koch Institute; Omid Veiseh, Ph.D., of Rice University; José Oberholzer, M.D., of the University of Virginia; and Arturo Vegas, Ph.D., of Boston University.
©2017 PR Newswire. All Rights Reserved.